Pet Cancer Therapeutics Market Analysis & Forecast: 2026-2033

Pet Cancer Therapeutics Market  Size and Forecast – 2026 To 2033

The Pet Cancer Therapeutics Market is anticipated to grow at a CAGR of 8.3% with USD 11.7 Bn share in 2026 and is expected to reach USD 18.7 Bn in 2033. Rising pet ownership, greater awareness of animal health, and the increasing incidence of cancer in pets drive the Pet Cancer Therapeutics Market. As of 2024, 66% of U.S. households, around 86.9 million homes own a pet.

Key Takeaways

• Chemotherapy holds the largest market share of 42.2% in 2026 owing to the rising incidence of cancer in pets. According to the American Veterinary Medical Association, about 25% of dogs develop cancer in their lifetime, rising to 50% for those aged 10 and above.
• Horse expected to hold largest market share of 47.7% in 2026 owing to its increasing incidence of equine cancers. Equine sarcoids represent 30% of all equine tumors and 70% of equine skin tumors.
• Oral acquired the prominent market share of 39.7% in 2026 owing to the improved pet owner compliance.
• Lymphoma captures the largest market share of 32.6% in 2026 owing to the high prevalence of lymphoma in pets. Lymphoma is a common canine cancer, comprising 14% of all dog malignancies and 90% of hematopoietic tumors, with up to 107 cases per 100,000 dogs.
• By Region, Asia Pacific is expected to acquire the dominant share of 39.20% in 2026 owing to its rapid growth in pet ownership. Pet ownership in India is rising fast, with the population expected to reach 43.9 million by 2026, up from 33.6 million in 2023, driven mainly by urban millennials and pandemic-era adoptions.

Current Events and Their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Request Free Sample

Horse expected to hold largest market share

Horse expected to hold largest market share of 47.7% in 2026 owing to its growth in equine specialty veterinary care. The horse segment in the pet cancer therapeutics market is expanding as veterinarians diagnose more equine cancers such as melanoma, sarcoids, and squamous cell carcinoma. Horse owners actively invest in advanced cancer treatments and specialized veterinary care due to the high economic and emotional value of horses. Expanding equine hospitals, improved diagnostic tools, and growing awareness of treatable tumors support market growth. Advancements in equine oncology therapies, along with a strong focus on preserving performance, mobility, and quality of life, further drive treatment adoption.

Why is Chemotherapy Acquiring the Largest Market Share?

To learn more about this report, Request Free Sample

Chemotherapy holds the largest market share of 42.2% in 2026. The rising incidence of cancer among aging dogs and cats continues to drive demand for chemotherapy in the pet cancer therapeutics market. Veterinarians widely use chemotherapy because it effectively treats multiple cancers, including lymphoma and mast cell tumors, while remaining more affordable than many advanced therapies. Pet owners increasingly invest in cancer care due to stronger emotional attachment to companion animals. At the same time, expanding veterinary oncology facilities and the development of safer chemotherapy protocols with reduced side effects are strengthening adoption of chemotherapy treatments in veterinary medicine. For instance, in May 2026, Researchers at Purdue University College of Veterinary Medicine’s Werling Comparative Oncology Research Center have treated the first dogs in two clinical trials using focused ultrasound for osteosarcoma and lymphoma. The team applies this tumor ablation approach, and after recovery, they administer adjuvant chemotherapy to continue treatment.

Oral acquired the prominent market share

Oral acquired the prominent market share of 39.7% in 2026 owing to the growing demand for home-based pet care. Veterinarians and pet owners increasingly choose the oral segment in the pet cancer therapeutics market because it allows easy, non-invasive treatment at home. Oral therapies improve treatment compliance, reduce stress for pets, and minimize frequent clinic visits. Pharmaceutical companies develop targeted oral drugs and enhance formulations with palatable and chewable options to boost acceptance. Rising demand for cost-effective long-term cancer management and the growing use of oral medications alongside other therapies further drive growth in veterinary oncology markets. For instance, in May 2026, Rigel Pharmaceuticals, Inc. has signed an exclusive global license agreement with Arvinas, Inc. and Pfizer Inc., pending regulatory approval, to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant), the first FDA-approved oral PROTAC therapy.

Which Application hold the largest market share?

Lymphoma captures the largest market share of 32.6% in 2026. The lymphoma segment in the pet cancer therapeutics market grows as veterinarians diagnose increasing cases of this common cancer in dogs and cats. Oncology specialists actively use effective chemotherapy protocols such as CHOP-based regimens, which deliver strong treatment responses. Advanced diagnostic tools like flow cytometry and immunophenotyping improve detection and classification accuracy. Rising pet humanization, greater awareness of early symptoms, and expanding veterinary oncology services support treatment adoption. Advances in combination therapies and supportive care further improve patient outcomes. For instance, in December 2025, Citius Oncology, Inc. launched LYMPHIR, an IL-2 receptor–directed fusion protein approved by the U.S. Food and Drug Administration for treating adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after prior systemic therapy.

Pet Cancer Therapeutics Market Trends

• Rising adoption of advanced veterinary oncology treatments: Advanced treatments such as chemotherapy, targeted therapies, immunotherapy, and oral oncology drugs are improving treatment options for companion animals. For instance, CHOP-based chemotherapy in canine lymphoma can induce remission in around 80–95% of dogs, with median survival of 8–12 months in many reported cases. In January 2026, the U.S. FDA granted full approval to Laverdia (verdinexor tablets) as the first oral treatment for lymphoma in dogs.
• Increasing demand for personalized veterinary medicine: Molecular profiling, genomic testing, PCR-based diagnostics, and liquid biopsy are supporting biomarker-driven treatment planning in canine oncology. A 2024 review noted that molecular genetic characterization of canine tumors is becoming important for precision veterinary cancer care, while liquid biopsy tests can detect cancer-associated biomarkers or genomic mutations from blood samples and support diagnosis/monitoring in dogs.
• Expanding pet insurance and higher owner spending on oncology care: Pet insurance is improving the affordability of expensive cancer diagnostics and treatments. NAPHIA reported 7.03 million insured pets in North America at year-end 2024, up 12.2% from 2023; in the U.S., insured pets reached 6.41 million, with dogs accounting for 75.6% of insured pets.

Regional Insights

To learn more about this report, Request Free Sample

Asia Pacific dominates owing to expansion of veterinary healthcare infrastructure

Asia Pacific is expected to acquire the dominant share of 39.20% in 2026. Rising pet ownership across Asia Pacific drives higher demand for advanced veterinary care as pet owners increasingly invest in treating serious illnesses. Stronger human–animal bonds encourage owners to seek specialized cancer treatments for pets. Veterinarians and healthcare providers improve diagnosis through better screening tools and technologies. Pharmaceutical companies expand investment in targeted oncology drugs, while veterinary networks grow and modernize. Wider adoption of pet insurance also improves affordability and access, enabling more clinics in urban and rural areas to offer cancer therapeutics. For instance, in May 2026, EGS Health launched Medicas Comprehensive Cancer Care (MC3), a nationwide platform that coordinates cancer care in India and provides patients access to multidisciplinary oncology expertise, second opinions, and personalized treatment guidance.

North America Pet Cancer Therapeutics Market Trends

The North America pet cancer therapeutics market is evolving as veterinary clinics and specialty hospitals increasingly adopt advanced oncology treatments for companion animals. They use targeted therapies, immunotherapies, and precision medicine to improve survival outcomes. Rising awareness among pet owners and growing veterinary spending drive demand for innovative treatment options. Pharmaceutical companies expand research pipelines and strengthen collaborations with veterinary institutions. They also advance minimally invasive diagnostics and personalized care approaches, which continue to shape the region’s market development and treatment landscape.

India Pet Cancer Therapeutics Market Trends

In India, rising awareness of companion animal health is driving the evolution of the pet cancer therapeutics market. Pet owners increasingly seek advanced veterinary oncology services, while clinics expand specialty care and upgrade diagnostic capabilities. Veterinary hospitals and pharmaceutical companies collaborate more closely to introduce immunotherapy and targeted treatments. Urbanization and stronger pet humanization trends increase demand for advanced cancer care. Growth in pet insurance awareness and development of specialized diagnostic centers further strengthen oncology services in major urban areas.

United States Pet Cancer Therapeutics Market Trends

In the United States, growing numbers of pet owners prioritize specialized oncology care for companion animals, driving the expansion of the pet cancer therapeutics market. Veterinary hospitals actively expand cancer treatment services and adopt advanced diagnostic tools such as imaging and molecular testing. Pharmaceutical companies develop targeted therapies and immunotherapies for pets. Research institutes and veterinary clinics collaborate to accelerate innovation. Pet humanization encourages earlier diagnosis and treatment, while pet insurance growth and specialty oncology centers improve access to advanced cancer care nationwide. For instance, in October 2025, Akston Biosciences Corporation initiated a clinical study of its Ambifect Fc-fusion immunotherapy targeting PD-L1 in dogs with solid tumors. The trial, conducted with Purdue University College of Veterinary Medicine, enrolled its first patient, an 11-year-old Dutch shepherd named Rocco diagnosed with high-grade soft tissue sarcoma.

Who are the Major Companies in Pet Cancer Therapeutics Industry

Some of the major key players in Pet Cancer Therapeutics are Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.

Key News

• In August 2025, Intas Pharmaceuticals has launched HETRONIFLY (serplulimab), the first PD-1 inhibitor approved for extensive-stage small cell lung cancer, in India following its European rollout. The company introduced the therapy through a licensing agreement with Shanghai Henlius Biotech, strengthening its oncology portfolio and expanding access to advanced cancer treatments.

Market Report Scope

Pet Cancer Therapeutics Market Report Coverage

Analyst Opinion

• Pet cancer therapeutics is driven more by clinical necessity than discretionary spending, as studies estimate that nearly 1 in 4 dogs and 1 in 5 cats will develop cancer during their lifetime, making oncology one of the most critical unmet needs in veterinary care rather than an optional specialty.
• The burden of late-stage diagnosis remains a major catalyst for treatment demand, with veterinary oncology literature indicating that a significant proportion of companion animal cancers are detected only after symptoms appear, when surgical intervention alone is insufficient and multimodal therapies such as chemotherapy, immunotherapy, and targeted drugs become necessary.
• Adoption of advanced veterinary oncology treatments is accelerating due to measurable clinical outcomes, with immunotherapy approaches such as canine melanoma vaccines demonstrating extended survival benefits in treated cases, while targeted therapies are increasingly used in mast cell tumors, reinforcing a shift toward precision-based veterinary cancer care and driving broader acceptance of high-value therapeutics in clinical practice.

Market Segmentation

• By Therapy Type: (Revenue, USD Bn, 2021-2033)
  • Chemotherapy
  • Targeted Therapy
  • Combination Therapy
  • Immunotherapy
• By Pet Type: (Revenue, USD Bn, 2021-2033)
  • Cat
  • Dog
  • Horse
• By Mode of Administration: (Revenue, USD Bn, 2021-2033)
  • Oral
  • Intravenous
  • Topical
• By Application: (Revenue, USD Bn, 2021-2033)
  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary and Squamous Cell Cancer
  • Others
• By Region: (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Aratana Therapeutics, Inc.
  • AB Science
  • Boehinger Ingelheim International GmbH
  • Zenoaq
  • Morphogenesis, Inc.
  • VetDC, Inc.
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Rhizen Pharmaceuticals SA
  • Oasmia Pharmaceuticals AB
  • Zoetis

Sources

Primary Research interviews

• Interviews with veterinary oncologists, small animal practitioners, and specialty veterinary hospital surgeons involved in cancer diagnosis and treatment
• Discussions with veterinary pharmaceutical manufacturers developing oncology drugs for companion animals
• Inputs from veterinary diagnostic laboratory experts focusing on histopathology and molecular testing

Databases

• PubMed veterinary oncology and comparative oncology datasets
• National veterinary clinical case registries and hospital treatment records
• Global animal health surveillance and adverse drug reaction databases
• University veterinary research repositories and thesis archives

Magazines

• Veterinary Practice News
• Today’s Veterinary Business
• Veterinary Times
• Clinician’s Brief (veterinary edition)

Journals’

• Journal of Veterinary Internal Medicine
• Veterinary and Comparative Oncology
• Frontiers in Veterinary Science
• Journal of the American Veterinary Medical Association (JAVMA)

Newspapers:

• The Hindu (science and health section)
• The Times of India (health and lifestyle coverage)
• The Indian Express (science reporting)
• Financial Express (healthcare innovation coverage)

Associations

• World Small Animal Veterinary Association (WSAVA)
• American Veterinary Medical Association (AVMA)
• Veterinary Cancer Society
• Indian Veterinary Association

Public Domain sources

• World Organisation for Animal Health (WOAH) publications
• Government veterinary public health reports
• University open-access veterinary oncology studies
• Clinical trial registries for veterinary therapeutics

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 10 years